With the rapidly growing body of evidence on the role of metabolic dysregulations in breast carcinogenesis, inhibitors of PI3K-AKT signaling, already used in the treatment setting, have been explored for breast cancer prevention, but adverse effects such as hyperglycemia and diarrhea prohibit their application in the prevention setting [13]. Here, AKT1 is linked to breast carcinoma.